|
国际站:p-SCN-Bn-DOTA
CAS:127985-74-4
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:p-SCN-Bn-DOTA 是一种双功能螯合剂。 p-SCN-Bn-DOTA可同时螯合放射性核素和连接单克隆抗体用于肿瘤放射免疫治疗[1][2]。
体外:p-SCN-Bn-DOTA 与 5 种不同的金属离子络合:In(III)、Y(III)、Lu(III)、Gd(III) 和 Cu(II)[2]。
参考文献:[1]. Vera DRB, et, al. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 2011 Jun;26(3):287-97.[2]. Giannini G, et, al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-6-29 21:35
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社